{"organizations": [], "uuid": "85934c4846243563e1c77ae293f66da00b17bea9", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180504.html", "section_title": "Archive News &amp; Video for Friday, 04 May 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-agios-qtrly-loss-per-share-163/brief-agios-qtrly-loss-per-share-1-63-idUSASC09ZVU", "country": "US", "domain_rank": 408, "title": "BRIEF-Agios Qtrly Loss Per Share $1.63", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.013, "site_type": "news", "published": "2018-05-04T19:23:00.000+03:00", "replies_count": 0, "uuid": "85934c4846243563e1c77ae293f66da00b17bea9"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-agios-qtrly-loss-per-share-163/brief-agios-qtrly-loss-per-share-1-63-idUSASC09ZVU", "ord_in_thread": 0, "title": "BRIEF-Agios Qtrly Loss Per Share $1.63", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "agios pharmaceuticals inc", "sentiment": "negative"}, {"name": "thomson reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 4 (Reuters) - Agios Pharmaceuticals Inc:\n* AGIOS PROVIDES BUSINESS UPDATE ON DISCOVERY RESEARCH STRATEGY AND PIPELINE, PROGRESS ON CLINICAL PROGRAMS, COMMERCIAL LAUNCH PREPARATIONS AND REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AT INVESTOR DAY\n* Q1 REVENUE $8.8 MILLION VERSUS I/B/E/S VIEW $10.6 MILLION\n* AGIOS PHARMA-SEES ENOUGH CASH,CASH EQUIVALENTS,MARKETABLE SECURITIES AS OF MARCH 31,AMONG OTHERS,TO FUND OPERATING EXPENSES,CAPEX THROUGH AT LEAST 2022 END\n* QTRLY LOSS PER SHARE $1.63 * Q1 EARNINGS PER SHARE VIEW $-1.63 â€” THOMSON REUTERS I/B/E/S Source text for Eikon: Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-05-04T19:23:00.000+03:00", "crawled": "2018-05-05T12:04:25.009+03:00", "highlightTitle": ""}